SERVIER
Updates & Highlights
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Medical Dialogues · 4 days ago
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
Oncodaily · 4 days ago
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
TradingView · 5 days ago
Recent Openings
View all 1 jobsCulture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Competitive Salary
Market-rate compensation
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at SERVIER?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentServier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Servier to Acquire Edgewise's Muscular Dystrophy Drug in USD 2.65 Billion Deal
Medical Dialogues · 4 days ago
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
David K. Lee: Servier Announces Acquisition of Edgewise Therapeutics’ Neuromuscular Business
Oncodaily · 4 days ago
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
Edgewise Therapeutics Stock Hits Record High on $2.65B Servier Deal
TradingView · 5 days ago
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
Servier to buy Edgewise’s muscular dystrophy biz in $2.65bn deal
BioXconomy · 5 days ago
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Servier to acquire Edgewise’s muscular dystrophy business for $2.65bn
Pharmaceutical Technology · 5 days ago
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
Servier Moves Into Muscular Dystrophy, Paying $1.5B for Assets From Edgewise Therapeutics
MedCity News · 5 days ago
Servier bets up to $2.7B for Edgewise's late-stage muscular dystrophy asset
Servier bets up to $2.7B for Edgewise's late-stage muscular dystrophy asset
FirstWord Pharma · 5 days ago
Edgewise sells muscular dystrophy assets to Servier for $2.65B
Edgewise sells muscular dystrophy assets to Servier for $2.65B
BioWorld News · 6 days ago
Servier buys into muscular dystrophy with potentially $2.7B deal
Servier buys into muscular dystrophy with potentially $2.7B deal
BioPharma Dive · 6 days ago
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Pr...
PR Newswire · 6 days ago
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal
BioSpace · 6 days ago
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
Servier wagers $2.65bn on Edgewise muscular dystrophy drug
pharmaphorum · 6 days ago
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio
Pharmaceutical Executive · 6 days ago
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
Servier buys Edgewise muscular dystrophy business for up to US$2.65bn
European Biotechnology Magazine · 6 days ago
Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
PR Newswire · 6 days ago
Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
Servier to buy Edgewise Therapeutics’ muscular dystrophy drug
statnews.com · 6 days ago
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
Servier inks $2.6B buyout of Edgewise’s muscular dystrophy unit to beef up neurology pipeline
Fierce Biotech · 6 days ago
Servier to spend up to $2.65B on Edgewise muscular dystrophy drugs
Servier to spend up to $2.65B on Edgewise muscular dystrophy drugs
Stock Titan · 6 days ago
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business
PR Newswire · 6 days ago
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
Servier to Present Extended Follow-Up Results from the Phase 3 INDIGO Trial Showing Durable and Sustained Treatment Benefits of VORANIGO® (vorasidenib) at ASCO 2026
PR Newswire · 6 days ago